This post was originally published on this site A Phase 1/2 trial assessing Oncternal Therapeutics‘ cirmtuzumab plus Imbruvica (ibrutinib) for the treatment of B-cell cancers is opening a Phase 1b extension part to continue studying the combination in people with mantle cell lymphoma (MCL), the company announced. The expansion was based on positive interim results from…
This post was originally published on this site In a lighthearted twist on a serious goal of raising awareness and funds for prostate cancer, the Movember Foundation is again encouraging gents to join glitterati in celebrating the moustache. The annual event is called Movember, a blending of the Australian-English “mo” for moustache with “November,” the month…
This post was originally published on this site Adding Lynparza (olaparib) to Avastin (bevacizumab) as a first-line maintenance treatment significantly delayed disease progression in women with advanced ovarian cancer — regardless of BRCA mutation status — interim data from a Phase 3 study show. This maintenance therapy was given after partial or complete response to first-line platinum-based chemotherapy. The…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted its Regenerative Medicine Advanced Therapy (RMAT) designation to the investigational therapy CT053 for the treatment of relapsed or refractory multiple myeloma. The RMAT designation is given to regenerative therapies intended to treat, modify, reverse, or cure a serious…
This post was originally published on this site The European Commission (EC) has approved a combination regimen of Bavencio (avelumab) injections plus Inlyta (axitinib) tablets for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC), the most common type of kidney cancer. The combination can be used in patients regardless of their predicted…
This post was originally published on this site People with HER-positive advanced breast cancer who received multiple HER-targeted therapies have significantly better survival outcomes — including overall survival and survival without disease progression — when given a combination of Seattle Genetics‘ tucatinib plus standard trastuzumab and Xeloda (capecitabine), results from a Phase 2 trial show.…
This post was originally published on this site Treatment with Copiktra (duvelisib) doubles response rates compared with Arzerra (ofatumumab), and significantly extends the time until disease progression or death in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two previous therapies, a Phase 3 trial revealed. The…
This post was originally published on this site Stereotactic body radiation therapy (SBRT) — a form of targeted, high-dose radiation therapy — significantly extends the time without detectable disease progression when given to prostate cancer patients with limited metastatic lesions, data from a Phase 2 trial show. These findings were presented at the recent 2019 American…
This post was originally published on this site Women with ovarian cancer who are partially sensitive to platinum-based chemotherapy may benefit from a new combination therapy — but safety concerns need to be addressed first, a study suggests. The new study proposes a combination of trabectedin and bevacizumab with platinum-based chemotherapy for these patients, whose disease…
This post was originally published on this site I-Mab Biopharma is expanding to mainland China its ongoing clinical studies assessing MorphoSys‘ investigational antibody therapy MOR202 (TJ202) as treatment for people with multiple myeloma, the company announced. The decision comes after an Investigational New Drug clearance issued by China’s National Medical Products Administration (NMPA). The ongoing…
